Upfront tandem autologous non-myeloablative allogeneic stem cell transplant in high-risk multiple myeloma: a long-term single-centre experience

被引：1
作者：
Nguyen, Phillip C. [1 ]
Muirhead, Jenny [1 ]
Tan, Joanne [1 ]
Kalff, Anna [1 ,2 ]
Bergin, Krystal [1 ,2 ]
Walker, Patricia [1 ]
Spencer, Andrew [1 ,2 ]
机构：
[1] Monash Univ, Alfred Hlth, Dept Clin Haematol, Melbourne, Vic, Australia
[2] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2022年 / 52卷 / 07期
关键词：
multiple myeloma; transplant; high risk; allogeneic; CYTOGENETICS; CONSENSUS; IFM99-03; STANDARD; OUTCOMES;
D O I：
10.1111/imj.15842
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The role of upfront non-myeloablative allogeneic stem cell transplantation (NMA alloSCT) in high-risk multiple myeloma (HR-MM) is unclear. We evaluated outcomes of NMA alloSCT following autologous stem cell transplant (ASCT) compared with ASCT alone for newly diagnosed HR-MM. Two-year progression-free survival was improved in the ASCT-NMA alloSCT group (44% vs 16%; P = 0.035), with a trend for improved overall survival (P = 0.118). These results suggest that ASCT-NMA alloSCT can be considered as upfront therapy in HR-MM.
引用
收藏
页码：1263 / 1267
页数：5
相关论文
共 22 条
  • [1] Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment
    Armeson, K. E.
    Hill, E. G.
    Costa, L. J.
    [J]. BONE MARROW TRANSPLANTATION, 2013, 48 (04) : 562 - 567
  • [2] Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up
    Bjorkstrand, Bo
    Iacobelli, Simona
    Hegenbart, Ute
    Gruber, Astrid
    Greinix, Hildegard
    Volin, Liisa
    Narni, Franco
    Musto, Pellegrino
    Beksac, Meral
    Bosi, Alberto
    Milone, Giuseppe
    Corradini, Paolo
    Goldschmidt, Hartmut
    de Witte, Theo
    Morris, Curly
    Niederwieser, Dietger
    Gahrton, Gosta
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) : 3016 - 3022
  • [3] A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
    Boyd, K. D.
    Ross, F. M.
    Chiecchio, L.
    Dagrada, G. P.
    Konn, Z. J.
    Tapper, W. J.
    Walker, B. A.
    Wardell, C. P.
    Gregory, W. M.
    Szubert, A. J.
    Bell, S. E.
    Child, J. A.
    Jackson, G. H.
    Davies, F. E.
    Morgan, G. J.
    [J]. LEUKEMIA, 2012, 26 (02) : 349 - 355
  • [4] A comparison of allografting with autografting for newly diagnosed myeloma
    Bruno, Benedetto
    Rotta, Marcello
    Patriarca, Francesca
    Mordini, Nicola
    Allione, Bernardino
    Carnevale-Schianca, Fabrizio
    Giaccone, Luisa
    Sorasio, Roberto
    Omede, Paola
    Baldi, Ileana
    Bringhen, Sara
    Massaia, Massimo
    Aglietta, Massimo
    Levis, Alessandro
    Gallamini, Andrea
    Fanin, Renato
    Palumbo, Antonio
    Storb, Rainer
    Ciccone, Giovannino
    Boccadoro, Mario
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (11) : 1110 - 1120
  • [5] Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma
    Campbell, P.
    Walker, P.
    Avery, S.
    Patil, S.
    Curtis, D.
    Schwarer, A.
    Wei, A.
    Kalff, A.
    Muirhead, J.
    Spencer, A.
    [J]. BLOOD CANCER JOURNAL, 2014, 4 : e213 - e213
  • [6] Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma
    Chiecchio, L.
    Protheroe, R. K. M.
    Ibrahim, A. H.
    Cheung, K. L.
    Rudduck, C.
    Dagrada, G. P.
    Cabanas, E. D.
    Parker, T.
    Nightingale, M.
    Wechalekar, A.
    Orchard, K. H.
    Harrison, C. J.
    Cross, N. C. P.
    Morgan, G. J.
    Ross, F. M.
    [J]. LEUKEMIA, 2006, 20 (09) : 1610 - 1617
  • [7] IMWG consensus on risk stratification in multiple myeloma
    Chng, W. J.
    Dispenzieri, A.
    Chim, C-S
    Fonseca, R.
    Goldschmidt, H.
    Lentzsch, S.
    Munshi, N.
    Palumbo, A.
    Miguel, J. S.
    Sonneveld, P.
    Cavo, M.
    Usmani, S.
    Durie, B. G. M.
    Avet-Loiseau, H.
    [J]. LEUKEMIA, 2014, 28 (02) : 269 - 277
  • [8] Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
    Garban, F
    Attal, M
    Michallet, M
    Hulin, C
    Bourhis, JH
    Yakoub-Agha, I
    Lamy, T
    Marit, G
    Maloisel, F
    Berthou, C
    Dib, M
    Caillot, D
    dePrijck, B
    Ketterer, N
    Harousseau, JL
    Sotto, JJ
    Moreau, P
    [J]. BLOOD, 2006, 107 (09) : 3474 - 3480
  • [9] Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation
    Kazmi, Syed M.
    Nusrat, Maliha
    Gunaydin, Hilal
    Cornelison, Amanda M.
    Shah, Nina
    Kebriaei, Partow
    Nieto, Yago
    Parmar, Simrit
    Popat, Uday R.
    Oran, Betul
    Shah, Jatin J.
    Orlowski, Robert Z.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    Bashir, Qaiser
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (11) : 687 - 693
  • [10] Knop S, 2014, BLOOD, V124
123